BRCA2 and cancer: This can be a source of distress for patients and their families and poses a unique problem in risk management (Freitas et al. 2018), but, since Patient B carries a BRCA2 VUS and developed MBC, our study demonstrates the urge for further investigations in order to clarify the impact of these variants, reclassify them, and fulfill the lack of predictive cancer models for their carriers.